References

Cancer statistics, 2023

2023 · External reference

Current therapy and drug resistance in metastatic castration-resistant prostate cancer

10.1016/j.drup.2023.100962 · 2023 · External reference

PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model

10.1016/j.omto.2020.06.014 · 2020 · External reference

Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens

10.1158/1535-7163.mct-12-0042 · 2012 · External reference

Priceman SJ.PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial

10.1038/s41591-024-02979-8 · 2024 · External reference

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

10.1038/s41591-022-01726-1 · 2022 · External reference

The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer

10.1158/1078-0432.ccr-20-3725 · 2021 · External reference

PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?

10.1177/17588359211053898 · 2021 · External reference

Expression of Prostate-Specific Membrane Antigen in Normal and Malignant Human Tissues

10.1007/s00268-005-0544-5 · 2006 · External reference

Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET/CT

10.1016/j.oooo.2018.01.011 · 2018 · External reference

Expression of glutamate carboxypeptidase II in the glial tumor recurrence evaluated in vivo using radionuclide imaging

10.1038/s41598-021-04613-w · 2022 · External reference

68-Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging

10.2967/jnumed.117.204677 · 2018 · External reference

Prostate-specific membrane antigen expression in normal and malignant human tissues

1997 · External reference

Preclinical evaluation of AMG 160, a next-generation bispecific T cell engager (BiTE) targeting the prostate-specific membrane antigen PSMA for metastatic castration-resistant prostate cancer (mCRPC)

10.1200/jco.2019.37.7_suppl.301 · 2019 · External reference

A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies

10.1126/scitranslmed.aaw7888 · 2020 · External reference

Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives

10.3390/cancers13030549 · 2021 · External reference

609O Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)

10.1016/j.annonc.2020.08.869 · 2026 · External reference

Pasotuxizumab, a Bite® Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings

10.2217/imt-2020-0256 · 2021 · External reference

Oral Toxicities of PSMA-Targeted Immunotherapies for The Management of Prostate Cancer

10.1016/j.clgc.2023.12.008 · 2024 · External reference

Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3

10.1016/j.abb.2004.12.003 · 2005 · External reference

IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity

10.1158/2159-8290.cd-20-1661 · 2021 · External reference

CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours

10.1038/s41586-022-04585-5 · 2022 · External reference

Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting

10.1038/s41467-023-40115-1 · 2023 · External reference

PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages

10.1136/jitc-2021-004400 · 2022 · External reference

Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma

2023 · External reference

T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans

10.1158/2326-6066.cir-13-0006 · 2013 · External reference

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

10.1182/blood-2007-12-128843 · 2008 · External reference

Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72

10.1023/a:1027396714623 · 1997 · External reference

Expression of the prostate-specific membrane antigen

1994 · External reference

Anti–prostate-Specific membrane antigen-based radioimmunotherapy for prostate cancer

10.1002/cncr.24795 · 2010 · External reference

In Vitro Characterization of Radiolabeled Monoclonal Antibodies Specific for the Extracellular Domain of Prostate-specific Membrane Antigen1

2000 · External reference

Anti-tumor effects of toxins targeted to the prostate specific membrane antigen

10.1002/pros.10117 · 2002 · External reference

An α-Particle Emitting Antibody ([213Bi]J591) for Radioimmunotherapy of Prostate Cancer1

2000 · External reference

A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer

10.1016/j.ejca.2013.01.024 · 2013 · External reference

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

10.1056/nejmoa2107322 · 2021 · External reference

Preliminary results from a phase 1/2 study of co-stimulatory bispecific PSMAxCD28 antibody REGN5678 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

10.1200/jco.2023.41.6_suppl.154 · 2023 · External reference

Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer

10.1080/2162402x.2017.1380764 · 2018 · External reference